Sanofi Advances Amlitelimab for Eczema Treatment with Positive Late-Stage Trial Results
Sanofi has revealed encouraging outcomes for its drug amlitelimab in two late-stage clinical trials for patients aged 12 and above suffering from moderate to severe eczema. The company reported favorable effectiveness and a safety profile in line with earlier observations, paving the way for regulatory submissions.